Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.

Name: Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
Author: McGuire, William P

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer. — المؤلف: McGuire, William P — BMC cancer 20190415

المؤلف: McGuire, William P
النشر: BMC cancer 20190415
الوصف: 1292 p.
الموضوعات: Adult؛ Aged؛ Aged, 80 and over؛ Antibodies, Monoclonal؛ Antineoplastic Combined Chemotherapy Protocols؛ Carcinoma, Ovarian Epithelial؛ Cisplatin؛ Constipation